Friday's top analyst upgrades and downgrades included Agnico-Eagle Mines, Biogen, Exelon, Meta Platforms, New York Times, PulteGroup, Snap and Vertex Pharmaceutical.
Thursday afternoon's top analyst upgrades and downgrades included CME Group, Etsy, NXP Semiconductors, Shell Midstream, Walmart and more.
Thursday’s top analyst upgrades and downgrades included Baker Hughes, BioMarin Pharmaceutical, Cisco Systems, Haliburton, Macy’s, Schlumberger and Sherwin-Williams.
Tuesday afternoon's top analyst upgrades and downgrades included Chipotle Mexican Grill, Lululemon Athletica, Kroger, Netflix and Nike.
Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
Friday’s top analyst upgrades and downgrades included BP, Cloudflare, Expedia, FireEye, Marathon Oil, Moderna, Pinduoduo, Vertex Pharmaceuticals and ViacomCBS.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including Acceleron Pharma, BioNTech, CyberArk Software, Five9 and Vertex Pharmaceuticals.
Thursday’s top analyst upgrades and downgrades included AutoNation, Enbridge, Gap, JinkoSolar, Micron Technology, Nvidia, Tractor Supply, Twilio and Vertex Pharmaceuticals.
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Celsius, Nasdaq, SmartSheet, Twilio and Zoom Video.
Here are five notable health care laggard stocks that appear to have plenty of upside potential. Most of them are dividend payers too.
Wednesday's top analyst upgrades and downgrades included Applied Materials, Caterpillar, Costco Wholesale, JPMorgan, Spotify, Vertex Pharmaceutical, Vornado Realty Trust and Whiting Petroleum.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth…
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
